ELAN is hoping to double its share of the multiple sclerosis treatment market, — through its headline drug, Tysabri — to 20%, within the next four years.

ELAN has taken a 24% stake in US firm Proteotasis Therapeutics and said that it is likely to do another licensing deal within the next six months.